Annals of Hematology

, Volume 89, Issue 4, pp 425–426

Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART

  • Sabine Blum
  • Matthias Cavassini
  • Jean-François Lambert
  • Aurélie Fayet
  • Marc Schapira
  • Martine Jotterand
Letter to the Editor

References

  1. 1.
    List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–65CrossRefPubMedGoogle Scholar
  2. 2.
    Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380–6PubMedGoogle Scholar
  3. 3.
    Haslett PA, Hanekom WA, Muller G et al (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187:946–55CrossRefPubMedGoogle Scholar
  4. 4.
    Giagounidis A, Fenaux P, Mufti GJ et al (2008) Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 87:345–52CrossRefPubMedGoogle Scholar
  5. 5.
    Jacobson JM, Greenspan JS, Spritzler J et al (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336:1487–1493CrossRefPubMedGoogle Scholar
  6. 6.
    Teo S, Noormohamed F, Youle M et al (2002) Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing. Aids 16:2355–6CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sabine Blum
    • 1
  • Matthias Cavassini
    • 2
  • Jean-François Lambert
    • 1
  • Aurélie Fayet
    • 3
  • Marc Schapira
    • 1
  • Martine Jotterand
    • 4
  1. 1.Service of HaematologyCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  2. 2.Department of Infectious DiseasesCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  3. 3.Division of Clinical PharmacologyCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  4. 4.Unité de cytogénétique du cancer, Service génétique médicaleCentre Hospitalier Universitaire VaudoisLausanneSwitzerland

Personalised recommendations